Table 5 Summary of the in vivo antineoplastic activities of TBK1 inhibitors

AMX

Antitumor efficacy in mouse models of melanoma, glioblastoma, pro-B-cell leukemia, prostate cancer, and K-RAS-activated/CTLA4 blockade-resistant lung cancer. AMX and TMZ given in combination display synergism in human glioma cells in xenografts.

[100, 246, 249, 250, 252, 274]

Compound I

Antitumor capabilities when combined with PD-L1 blockade in mouse models of colorectal carcinoma.

[244, 270]

GSK8612

Inhibits HCC development in animal models by attenuating the production of immunosuppressive cytokines, consequently allowing enhanced infiltration of CD8⁺ T cells into the tumor.

[222]

MMB

Affords increased survival and decreased spleen size in mouse models of ovarian carcinoma and AML, respectively, and displays synergism with trametinib in suppressing PDA growth in animals.

[231, 275, 276]

200A

Anticancer activity in mouse models of squamous cell carcinoma.

[244, 270]